Funder: National Institutes of Health
Due Dates: August 14, 2024 (Renewal/Resubmission/Revision) | January 16, 2025 (New) | August 14, 2025 (Renewal/Resubmission/Revision) | January 16, 2026 (New) | August 14, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $600,000 direct costs for the R61 phase (2 years); R33 phase (up to 3 years) has no set limit but must reflect project needs; total project period up to 5 years.
Summary: Supports exploratory clinical research to identify and validate novel non-invasive brain stimulation targets and mechanistic responses relevant to substance use disorder treatment.
Key Information: Applications must include clear, quantitative milestones for R61-to-R33 transition; preliminary data are not required; foreign and domestic applicants eligible.